Are you attending ASH 2022 in New Orleans, LA, USA?
Sign up to join us as we dive into the landscape of cytogenetic assays for the detection of structural variations (SV) in hematological malignancies, and learn why optical genome mapping (OGM) has gained significant popularity and adoption by cytogenetic labs. Hear from our Chief Medical Officer, Dr. Alka Chaubey, and industry colleagues in oncology and pathology, as they discuss the utility of OGM over dinner.
Medical guidelines for classifications of hematological malignancy subtypes are continuously updated and classical cytogenetic methods demonstrate significant limitations for understanding the complexity of genetic markers needed for the appropriate classification of the heme malignancy sub-type.
OGM offers a more precise and higher-resolution method for SV detection and alleviates the subjectivity and ambiguity that often accompanies classical methods, such as karyotyping and FISH. OGM not only accurately detects the structural variations of biological importance, it aids in the identification of cryptic genomic aberrations and novel biomarkers of significant relevance, thereby providing answers in a greater number of clinical research cases.
RSVP today to join us for dinner and to learn more – we’ll discuss real-life case studies from leading institutions around the world.
Date: Monday, December 12th 2022
Location: Saints & Sinners, 627 Bourbon St, New Orleans, LA 70130
Time: 8:00 PM
RSVP is required.
We look forward to seeing you in New Orleans!
Bionano’s annual virtual symposium begins on January 23, 2023.
Event doors will open at 6:30 AM PT/9:30 AM ET/2:30 PM CET
Event begins at 7:00 AM PT/10:00 AM ET/3:00 PM CET
Hear from 25+ global experts sharing how they drive discovery across multiple applications with optical genome mapping (OGM). Learn from presentations, engage in live Q&A, and view posters with the latest scientific research!
Day 1: Hematological Malignancies
Day 2: Solid Tumors
Day 3: Constitutional Genetic Diseases
Day 4: Cell Bioprocessing
Attendance at all sessions of interest is strongly encouraged! Presentations will be available on demand after Symposium 2023 concludes.
Sign up to View On-Demand for this information-packed Bionano-IPM webinar. Dr. Adam Smith describes how his organization, has evaluated optical genome mapping as a first-line test for hematologic malignancies specifically focusing on acute myeloid leukemia and replacing a legacy eosinophilic leukemia FISH panel.
Original Date: Tuesday, August 30, 2022
Adam Smith, Ph.D.
Director, Cancer Cytogenetics Laboratory | University Health Network, Toronto
Sign up to View On-Demand for this insightful Bionano-IPM webinar, that will offer a unique, combined perspective of a pathologist, Dr. Kanagal-Shamanna, and an oncologist, Dr. Garcia-Manero, on the utility of OGM in Myelodysplastic Syndromes (MDS), a type of hematologic malignancy, based on leading research conducted by their groups at the MD Anderson Cancer Center. And, take advantage of the live Q&A session following the presentations.
Original Date: Tuesday, November 15, 2022
Rashmi Kanagal-Shamanna, MD
Director, Molecular Diagnostic Lab | MD Anderson Cancer Center
Guillermo Garcia-Manero, MD
Chief, Section of Myelodysplastic Syndromes | MD Anderson Cancer Center